Dealmaking and Financing: Mergers and Acquisitions in the Pharmaceuticals and Biotech Industries
Monday August 18, 7:54 am ET
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ad445d/dealmaking_and_fin) has announced the addition of Decision Resources, Inc.'s new report "Dealmaking and Financing: Mergers and Acquisitions in Key Markets" to their offering.
Billion-dollar deals. Hostile takeovers. Reverse mergers. Bidding wars. All of these are signs that Big Pharma is hungry for deals and is aggressively seeking, assessing, and consummating alliances on several fronts. No facet of the biotech, specialty, or generics industries is being ignored; no technology platform, clinical product, or research program is unexplored or unexamined. Dealmaking has become the driving force that is bolstering R&D pipelines and promulgating innovative technology throughout drug discovery and development. In this report, which focuses on mergers and acquisitions (M&As) in the 18-month period from January 2007 through June 2008, we detail deals, the strategies that drove them, and the likely future role of M&As.
Get the Answers You Need to Shape Your Strategy:
- Multibillion-dollar M&As are not uncommon as Big Pharma and Big Biotech hunt for biologics, enabling technologies, and products to bolster specific therapy areas. What are the forces driving these acquisitions and the industry trends that are developing? Which companies are moving to become leaders in personalized medicine and biosimilars?
- Companies are evolving to become “hybrids” that have a hand in various market sectors, such as branded pharmaceuticals, generics, and biosimilars. What is the value of this strategy? Which companies are pursuing it, and how successful have they been? What, according to our expert commentator, does the Daiichi Sankyo/Ranbaxy deal reveal about this trend?
- China has been identified as a national market that will become a center of gravity for the pharmaceutical industry in the near future. How are foreign investors tapping this potential? What activities are native Chinese pharmaceutical companies pursuing? How is the traditional Chinese medicines (TCM) market evolving? What does our expert commentator point out about opportunities in China?
- M&As are likely to remain a valuable strategy in the pharmaceutical and biotech dealmaking arsenal. What are five key likely developments that will sustain the wave of M&As over the next few years?
Scope:
- Key markets: technology types, therapeutic areas, drug types (biologics, biosimilars, generics), geographic markets.
- Tables: ten tables detail M&A activity on a variety of fronts: billion-dollar deals, technology-driven deals, therapeutic-area-focused deals, IPO-less acquisitions, company type (big pharma, big biotech, specialty pharma, generics), and more.
- Expert Commentaries: Greg B. Scott, founder and president, ChinaBio Accelerator and cofounder and president, Life Science Angels, discusses early-stage opportunities in China; Peter Wittner, Interpharm Consultancy, explores the future role of hybrid companies.
Key Topics Covered:
Executive Summary
Strategic Considerations
Stakeholder Implications
Introduction
Billion-Dollar Mergers and Acquisitions
Technology Access
Largest Biologics Deals
Protein Engineering
Biosimilar Capabilities
Most Active Therapy Areas
IPO-Less Private Company Acquisitions
Extending International Reach to China
Competitive Advantage Through Size and Scale of Operations
Modernizing Traditional Chinese Medicines
Moving Up the Pharmaceutical Value Stream
Access to Money and Capital Markets
U S -Based IPOs
Reverse Mergers
Acquisition by a Foreign Company
Japanese M&A Strategies
Biologics-Related Acquisitions
Expanded Global Presence
Consolidation to Strengthen Domestic Presence
Bringing Branded and Generic Businesses Together
Big Pharma
Building a Leading Position in Personalized Medicine
Gobbling Up Ever-Earlier Stages of Technology
Strengthening Therapy Areas
Acquisitions Related to Technology, Biologics, or Specific Diseases
Big Biotech’s Recent M&A Activities
Substantial Activity in Generics M&As
Five Expectations That Will Continue to Drive M&As
Expert Commentaries
Early-Stage Life Sciences Opportunities in China
Is the Hybrid Company the Future of the Pharmaceutical Industry?
List of Tables
1 Biologics-Related Mergers and Acquisitions, 2007-2008
2 Therapy Areas of Select Mergers and Acquisitions, 2007-2008
3 Acquisitions of Private, IPO-Less Companies, 2007-2008
4 Mergers and Acquisitions by Chinese Companies, 2007-2008
5 Mergers and Acquisitions Based on Traditional Chinese Medicines, 2007-2008
6 Mergers and Acquisitions by Chinese Companies That Gain Access to U S Markets, 2007-2008
7 Mergers and Acquisitions by Japanese Companies, 2007-2008
8 Select Big Pharma and Specialty Pharma Mergers and Acquisitions, 2007-2008
9 Big Biotech Mergers and Acquisitions, 2007
10 Generic- and Biosimilar-Based Mergers and Acquisitions, 2007-2008
List of Figures
1 Spectrum, Dealmaking and Financing Series
2 Billion-Dollar Mergers and Acquisitions, 2007-2008
3 Acquisition Values of Private IPO-Less Companies, 2007-2008
4 ChinaBioStock Index: Market Capitalization of 17 Chinese Companies Listed on U S Stock Exchanges, May 27, 2008
5 Sizes of Big Pharma’s Mergers and Acquisitions, 2007-2008
Some of the Companies Mentioned: (For more companies mentioned please follow the link provided below)
- 3SBio
- 454 Life Sciences
- Abbott
- Abrika Pharmaceuticals
- Actavis
- Adaltis
- Adams Respiratory Therapeutics
- Adnexus
- Agensys
- Alantos Pharmaceuticals
- Alcon
- Allergan
- Alliance BMP
- Alliance Boots
- Alnylam
- American Oriental Bioengineering
- AmeriPath
- Amgen
- Amgen-Dompe
- Apotex
- Apptec Laboratory Services
- Arrow Therapeutics
- Arysta LifeScience
- Astellas Pharma
- AstraZeneca
- Axcan Pharma
- AxiCorp
- AXM Pharma Shenyang
- Barr Pharmaceuticals
- BASF
- Bausch & Lomb
- Bayer
- Bayer Classics
- Beckman Coulter
- Beijing Boran Pharmaceutical
- Beijing Med-Pharm
- Beijing Tiancheng Haixin Pharmaceutical
- Benda Pharmaceutical
- Bentley Pharmaceuticals
- Be-Tabs
- Bio-Bridge Science
- Biocon
- Bioenvision
- BioExplorer
- Biogen Idec
- BioRexis
- Biosite
- BioVeris
- BioVitrum
- BMP Sunstone
- Boda
- Boehringer Ingelheim
- Borealis Infrastructure
- Bradley Pharmaceuticals
- Bristol-Myers Squibb
- Celgene
- Cerexa
- Changchun Xinan Pharmaceutical
- Charles River Laboratories
- China Aoxing Pharmaceutical
- China Bio
- China BioPharma
- China Biopharmaceuticals Holdings
- China Gene
- China Health Holdings
- China Kelun Pharmaceutical
- China Medical Technologies
- China Nepstar
- China Shenghuo Pharmaceutical Holdings
- China Sky One Medical
- ChinaBio Accelerator
- Chiron
- Chugai
- CoGenesys
- Coley Pharmaceutical Group
- Covance
- Cox Pharmaceuticals
- CuraGen
- CVC Capital
- Cytyc
- Dade Behring
- Daiichi Sankyo
- Dako
- Digene
- Domantis
- Dompe Biotec
- Dorom
- Dr. Reddy’s Laboratories
- Eisai
- Eli Lilly and Company
- Encysive Pharmaceuticals
- EndoArt
- EQT Partners
- Esprit Pharma
- Evans Medical
- Forest Laboratories
For more information visit researchandmarkets.com
Contact:
biz.yahoo.com
Research and Markets
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
Source: Research and Markets |
